Bial Portela, Portugal’s largest drugmaker, has released positive results for a pivotal Phase III non-inferiority study comparing the efficacy and safety of eslicarbazepine acetate (ESL; trade name Zebinix) to controlled release carbamazepine (CBZ-CR) as monotherapy in newly-diagnosed adult patients with partial-onset seizures (POS).
This pivotal Phase III trial was a randomized, double-blind, parallel-group, active-controlled and non-inferiority study, investigating the efficacy and safety of once-daily ESL (800 to 1,600mg/daily) as monotherapy treatment for newly diagnosed adults with partial-onset seizures in comparison with twice-daily CBZ-CR (400 to 1,200mg/daily).
To file for expanded indication
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze